Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 4
Subjects
- Location of subjects
- Finland
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Irritable bowel syndrome [X]Psychogenic IBS,Adaptive colitis,Colitides, Mucous,Colitis, Mucous,Colon spasm,Colon, Irritable,Functional bowel disease,IBD,IBS,IBS - Irritable bowel syndrome,IC - Irritable colon,Irritable bowel,Irritable bowel - IBS,irritable bowel syndrome,Irritable Bowel Syndromes,Irritable Colon,irritable colon,Irritable colon (disorder),Irritable colon - Irritable bowel syndrome,Irritable colon syndrome,Membranous colitis,Mucous Colitides,Mucous colitis,mucus colitis,Nervous colitis,Psychogenic IBS,psychogenic IBS,Spastic colitis,Spastic colon,spastic colon,Syndrome, Irritable Bowel,Syndromes, Irritable Bowel,Irritable bowel syndrome
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy Control
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- IBS (All patients)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- IBS patients fulfilled the Rome II criteria. All IBS patients.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 46
- Group 1 sample size Number of subjects in the case (exposed) group
- 62
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Human Intestinal Tract Chip
Statistical Analysis
- Statistical test
- T-Test
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Signature 1
Source: Figure 1.
Description: Differences Between Intestinal Microbiota in Healthy and IBS. NOTE. Genus-like phylogenetic groups for which the hybridization signal differed significantly between the healthy subjects and (one of the subtypes of) IBS patients are indicated. Gray shading represents phylogenetic groups with a decreased signal in IBS patients. a) Significant (q < .05) correlation. b) Strongly significant (q < .01) correlation.
Abundance in Group 1: decreased abundance in IBS (All patients)
Revision editor(s): Kwekuamoo
Signature 2
Source: Table 1.
Description: Differences Between Intestinal Microbiota in Healthy and IBS. NOTE. Genus-like phylogenetic groups for which the hybridization signal differed significantly between the healthy subjects and (one of the subtypes of) IBS patients are indicated. Gray shading represents phylogenetic groups with a decreased signal in IBS patients. a) Significant (q < .05) correlation. b) Strongly significant (q < .01) correlation.
Abundance in Group 1: increased abundance in IBS (All patients)
Revision editor(s): Kwekuamoo
